Gossamer Bio Inc expected to post a loss of 17 cents a share - Earnings Preview

Gossamer Bio

28/02/2025 13:35

Gossamer Bio Inc GOSS.OQ GOSS.O is expected to show a rise in quarterly revenue when it reports  results on March 3 (estimated) for the period ending December 31 2024

The San Diego California-based  company is expected to report revenue of $6.834 million, according to the mean estimate from 8 analysts, based on LSEG data.

‚ÄčLSEG's mean analyst estimate for Gossamer Bio Inc is for a loss of 17 cents per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ‚Äč

Wall Street's median 12-month price target for Gossamer Bio Inc is $8.00‚Äč, above‚Äč its last closing price of $1.19. ‚Äč‚Äč‚Äč

Previous quarterly performance (using preferred earnings measure in US dollars). ‚Äč

QUARTER ENDING
STARMINESMARTESTIMATE¬ģ
LSEG IBES ESTIMATE
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Sep. 30 2024
-0.12
-0.15
-0.14
Beat
5.3
Jun. 30 2024
0.31
0.23
0.22
Missed
-3.9
Mar. 31 2024
-0.19
-0.19
-0.19
Met
-0.5‚Äč
Dec. 31 2023
-0.19
-0.21
-0.21
Met
-1
‚Äč‚ÄčSep. 30 2023
-0.24
-0.26
-0.21
Beat
17.8
Jun. 30 2023
-0.48
-0.49
-0.45
Beat
8‚Äč
Mar. 31 2023
-0.52
-0.53
-0.52
Beat
1.8
Dec. 31 2022
-0.62
-0.62
-0.59
Beat
5.3

This summary was machine generated February 28 at 13:35 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)